Evidence map›Paper›PMID 36001596›Full record

ArticlePloS one2022

Relevance of COVID-19 vaccine on the tourism industry: Evidence from China.

Fredrick Oteng Agyeman, Zhiqiang Ma, Mingxing Li, Agyemang Kwasi Sampene, Israel Adikah, Malcom Frimpong Dapaah

Erratum issuedAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Fredrick Oteng AgyemanSchool of Management, Jiangsu University, Zhenjiang, P.R. China.ORCID 0000-0003-4615-2555
Zhiqiang MaSchool of Management, Jiangsu University, Zhenjiang, P.R. China.
Mingxing LiSchool of Management, Jiangsu University, Zhenjiang, P.R. China.
Agyemang Kwasi SampeneSchool of Management, Jiangsu University, Zhenjiang, P.R. China.
Israel AdikahSchool of Management, Jiangsu University, Zhenjiang, P.R. China.
Malcom Frimpong DapaahSchool of the Environment and Safety Engineering, Jiangsu University, Zhenjiang, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVaccination is indeed one of the interventional strategies available to combat coronavirus disease (COVID-19). This study emphasizes the relevance of citizens' acceptance of the COVID-19 vaccine in assisting global recovery from the pandemic and aiding the tourism industries to return to normalcy. This study further presented the impact of COVID-19 on the tourism industry in China. Also, the study confirmed the past performance of tourism in China to the current tourism-related COVID-19 effects from a global perspective by employing Australia's outbound tourism data from 2008 to 2020 on top 6 destinations, including China, Indonesia, New Zealand, Thailand, the United Kingdom, and the United States.

methodsJeffrey's Amazing Statistical Program (JASP) was used to analyze this study. The JASP statistical software was employed to accurately analyze the vaccines administered in China from December 15, 2020, to March 28, 2021.

resultsThe study results demonstrate an overwhelming acceptance of vaccines in China which will positively and significantly impact the globe's travel and tourism industries. Also, the study findings indicated that industries in tourism are hopeful of regaining the past losses. Further, the study results showed an enormous decline in death and new cases.

conclusionVaccine acceptance is relevant for the eradication of the COVID-19 pandemic. Therefore, neighborhood and individual-level acceptance of the vaccine will help reduce the challenges facing the tourism industries and the world. The researchers recommend that authorities should strictly check the vaccination certificates of visitors. Furthermore, hoteliers should put adequate measures to monitor all visitors who visit the various tourist destinations.

Indexed as

COVID-19PandemicsChinaCOVID-19 VaccinesHumansTourismUnited StatesVaccinationCOVID-19 Vaccines

Identifiers

PMID36001596
PMCPMC9401110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.